Insmed | INSM - Ebitda

Stock Price
109.10
Daily Change
-6.52 -5.64%
Monthly
-23.59%
Yearly
60.16%
Q2 Forecast
99.25

Insmed reported $-148.3M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
DBV Technologies USD -33.48M 5.55M Sep/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
Novartis USD 5.84B 235M Sep/2025
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026